Inspire Retires the Language of Its Own Crisis

Inspire Retires the Language of Its Own Crisis

For four quarters, Inspire Medical Systems' transcript read like a coding-and-reimbursement deposition. The words reimbursement uncertainty, WISER program, professional fee, modifier, C-code — those were the plot. On Monday night, they were nearly gone. The company's own keyword fingerprint for Q3 2026 is a different animal: expanding access at the top, followed by growth situation, return to growth, Inspire VI, RUC process, battery replacement, and cardiology based call point. The crisis vocabulary did not get resolved so much as it got promoted — from a live P&L problem to a 2028 option on a calendar.

That is the story. Not the quarter, which was bad: revenue of $206.7 million, down 7.9% year over year, adjusted operating income of $1.9 million against $10.9 million a year ago, adjusted EBITDA margin down 130 basis points to 18.3%. The story is that management finally put a number in front of 2027 after two consecutive calls of refusing to.

The guide is the tell

Go back to August. Asked about 2027, Tim Herbert said the company would not comment: “we don't want to make comments on guiding on '27 yet, but we like what is coming together” — Timothy Herbert, Chairman and Chief Executive Officer · 2026-08-03. Back in May, on the same subject, he was blunter: “it is premature to put too much detail around that today.” — Timothy P. Herbert, Chairman and Chief Executive Officer · 2026-05-04 On Monday, Matt Osberg delivered a full-year 2027 framework — low single-digit revenue growth — and, tellingly, he framed it with the same defensive clause the company used all year about its 2026 funnel:

As we look into 2027, based on our expectations for market growth, a more stable coding environment, growth initiative investments funded by Project Horizon, and a more significant contribution from battery replacement revenue, we are increasingly confident in our ability to return to growth and deliver low single-digit year-over-year revenue growth for the full year 2027.

Low single digit is the number that matters, and it is not a triumphant one. Robbie Marcus did the arithmetic on the call and landed on roughly 7% underlying U.S. growth once you normalize for the reimbursement hit — which is a sharp deceleration from the 12%–13% the company guided to in 2025 and the 10%–11% it floated as an early indication for 2026 a year ago. Herbert did not dispute the framing; he said the company expects to “continue to push that growth rate higher” — Tim Herbert, Chairman and Chief Executive Officer · 2026-11-02 over time. Daniel Markowitz of Evercore asked the right question — is this a prudent early view or are there offsets? — and got the answer that it is “the initial kind of based on where we are” — Tim Herbert, Chairman and Chief Executive Officer · 2026-11-02. Read that as: we are setting a bar we can clear, because we have missed bars before.

What actually changed: the hole is quantified, and the clock moved

The reimbursement damage is now a known quantity rather than a mystery. Osberg put it plainly:

We estimate that our third quarter results were adversely impacted by coding and reimbursement challenges by approximately $30 million. For the full year, we are currently estimating the total impact to be approximately $120 million.

That $120 million has been walked down through the year — $150 million, then $130 million, now $120 million — and it is lappable in 2027, which is most of why the guide exists at all. What genuinely changed since the summer is the long-dated plumbing. The Category I CPT code for single-lead hypoglossal nerve stimulation was approved and takes effect January 1, 2028; the RUC process for valuing it has started, with surveys out through the ENT society and a first panel meeting expected in January. And the final OPPS rule lands this week, with the July proposal pointing to a significant facility increase. Herbert's summary: “we feel confident that much of the disruption is behind us” — Tim Herbert, Chairman and Chief Executive Officer · 2026-11-02. The market, notably, has already accepted that framing — see below.

Worth flagging the risk that has not gone away. In February, Herbert was explicit that a new code cuts both ways: “there is always risk that the RUC would identify a lower payment from where 64582 is today.” — Timothy P. Herbert, Chairman and Chief Executive Officer (CEO) · 2026-02-11 Michael Sarcone raised it again on Monday, asking whether a faster Inspire V procedure could produce a professional fee that discourages new implanters. Herbert conceded the point — “there is always a risk of a reduction in reimbursement” — Tim Herbert, Chairman and Chief Executive Officer · 2026-11-02 — and leaned on sample size: Inspire V is now performed by well over a thousand surgeons, versus a much smaller base when the old code was valued. That is a real argument, but it is an argument, not a resolution.

Three new things hiding under a bad quarter

First, batteries. For the first time, Inspire broke out battery replacement as a discrete line of the growth story — patients implanted 2014–2016 are now cycling through an eleven-year battery. Keith Hinton asked directly about it, and Herbert's enthusiasm was unguarded: “it is the first time that we have actually called it out, and you are the first person to have the opportunity to ask the question between de novo and replacements” — Tim Herbert, Chairman and Chief Executive Officer · 2026-11-02. It is small, but it is high-margin, annuity-like revenue that did not exist before and does not depend on opening a single new center.

Second, the cardiology channel. Armed with TriNetX data associating Inspire with lower odds of stroke, heart attack and atrial fibrillation versus CPAP, management is funding a cardiology based call point — a referral engine pointed at atrial fibrillation patients who need an OSA assessment. Herbert was careful that this is not a surgical call point expansion: “We want the referrals.” — Tim Herbert, Chairman and Chief Executive Officer · 2026-11-02 That is the correct restraint given what happened the last time this company bolted on sales capacity.

Third, Inspire VI. A firmware upgrade to V that adds automatic sleep detection, in final algorithm development and validation, with “if we can get to the FDA next year, would be a good target” — Tim Herbert, Chairman and Chief Executive Officer · 2026-11-02. It matters less for revenue in 2027 than as the answer to the competitive question analysts keep asking. Herbert acknowledged competitors exist and are built into the assessment, but noted no meaningful impact yet.

The tape is not waiting for the call

Here is the tension. Inspire's stock is up 47% over the last ninety days, an unbroken run of seventeen weeks, and sits 12.5% off its September high. Yet it is still 79% below the July 2023 peak of $326. The company has been de-rated from a growth darling to something closer to a value multiple: price to revenue has compressed roughly 97% from its 2020 peak, and price to operating income has fallen from a 250x peak in 2024 to under 20x. The recovery bid is not about the multiple; it is about whether $850–860 million of 2026 revenue is a trough or a new normal.

The financials support a trough read. Revenue fell 8% year over year in the last reported quarter, yet gross margin ticked up 1.5 points to 85.5%, and the company ended the quarter with $453.1 million of cash, investments and no debt — effective net cash has more than doubled over the past year. YTD operating cash flow of $82.5 million against $64.5 million a year ago, during a revenue decline, is the single most credible thing management said all night. That is what buys the time to spend Project Horizon's $30 million of annualized capacity on forty new field roles and targeted marketing rather than on defending a P&L.

The bear case is equally simple: a company that spent 2026 explaining why its customers would not bill for its product is now asking investors to trust that the same customers will happily ramp into a low single-digit growth year, with an international business that just posted its first decline since early 2025 on German destocking and a fourth quarter that has to deliver a large sequential step-up to hit the guide. Inspire has earned skepticism. But it has also, for the first time in a year, stopped talking about its problems and started talking about return to growth — and put a number on it.